Gerresheimer Adjusts 2025 Guidance Amid Slower Market Growth

Gerresheimer AG has revised its 2025 financial guidance due to slower market growth and a subdued business performance. Preliminary results for the first nine months reveal a 14.6% increase in revenues to EUR 1,681.4 million, but organic revenues fell by 1.8%.

The company anticipates an organic revenue decline of 2% to 4% for the full year, with an adjusted EBITDA margin of 18.5% to 19%. Demand remains weak in the cosmetics and oral liquids sectors.

Gerresheimer has launched a transformation program to optimize costs and performance. The company also expects a stronger fourth quarter driven by production ramp-ups for drug delivery systems.

The separation of its Moulded Glass division into an independent unit is progressing and should be completed by 2026, allowing Gerresheimer to focus more on the pharma and biotech industries.